Neurodegenerative Disorder-Targeting Compound 1 |
| Catalog No.GC31311 |
Neurodegenerative Disorder-Targeting Compound 1 is a calpain inhibitor (extracted from patent WO2010128102A1, compound 63) .
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1254699-12-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Neurodegenerative Disorder-Targeting Compound 1 is a carboxamide compound, used in the research of neurodegenerative disorders.
Neurodegenerative Disorder-Targeting Compound 1 can be used in the research of neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease[1].
[1]. MACK, Helmut., et al. CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS. WO 2010128102 A1.
Average Rating: 5 (Based on Reviews and 16 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *